ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 132,99
0,51%
Dow Jones
39 671,04
0,00%
DAX
18 759,96
0,42%
Brent Oil
82,405
1,07%
Bitcoin
69 753,97
0,94%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Actualités

AZN

AstraZeneca (AZN)

AstraZeneca PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateHeureSourceTitreSymboleSociété
23/05/202413h00Business WireAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:AZNAstraZeneca PLC
22/05/202413h00Business WireAstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​NASDAQ:AZNAstraZeneca PLC
22/05/202400h44Business Wireアストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定NASDAQ:AZNAstraZeneca PLC
21/05/202417h37Business WireAstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 anNASDAQ:AZNAstraZeneca PLC
21/05/202417h36Business WireAstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030NASDAQ:AZNAstraZeneca PLC
21/05/202413h18IH Market NewsCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More NewsNASDAQ:AZNAstraZeneca PLC
21/05/202412h08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
21/05/202408h00Business WireAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030NASDAQ:AZNAstraZeneca PLC
19/05/202423h17Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary diseaseNASDAQ:AZNAstraZeneca PLC
13/05/202413h16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNASDAQ:AZNAstraZeneca PLC
06/05/202408h00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:AZNAstraZeneca PLC
02/05/202413h00Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
01/05/202413h05Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioNASDAQ:AZNAstraZeneca PLC
29/04/202413h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralowNASDAQ:AZNAstraZeneca PLC
25/04/202414h00PR Newswire (US)AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:AZNAstraZeneca PLC
25/04/202413h53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:AZNAstraZeneca PLC
25/04/202413h52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:AZNAstraZeneca PLC
25/04/202408h00Business WireQ1 2024 resultsNASDAQ:AZNAstraZeneca PLC
16/04/202413h00Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trialNASDAQ:AZNAstraZeneca PLC
12/04/202413h05IH Market NewsParamount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202413h24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202413h00Business WireFASENRA approved for treatment of children aged 6 to 11 with severe asthmaNASDAQ:AZNAstraZeneca PLC
06/04/202405h10Business WireENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsNASDAQ:AZNAstraZeneca PLC
06/04/202403h43Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsNASDAQ:AZNAstraZeneca PLC
05/04/202413h00Business WireIMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trialNASDAQ:AZNAstraZeneca PLC
02/04/202413h00Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
02/04/202408h00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerNASDAQ:AZNAstraZeneca PLC
01/04/202413h00Business WireVOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNHNASDAQ:AZNAstraZeneca PLC
27/03/202411h54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNASDAQ:AZNAstraZeneca PLC
26/03/202412h20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Dernières Valeurs Consultées

USOTC
FRPRQ
4D Pharma (CE)
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés